Sustained response to erlotinib and rapamycin in a patient with pediatric anaplastic oligodendroglioma.
Identifieur interne : 000041 ( Main/Exploration ); précédent : 000040; suivant : 000042Sustained response to erlotinib and rapamycin in a patient with pediatric anaplastic oligodendroglioma.
Auteurs : Laura C. Geben [États-Unis] ; Bret C. Mobley [États-Unis] ; Asa A. Brockman [États-Unis] ; Devang Pastakia [États-Unis] ; Rob Naftel [États-Unis] ; Rebecca A. Ihrie [États-Unis] ; Adam J. Esbenshade [États-Unis]Source :
- Pediatric blood & cancer [ 1545-5017 ] ; 2020.
Abstract
One goal of precision medicine is to identify mutations within individual tumors to design targeted treatment approaches. This report details the use of genomic testing to select a targeted therapy regimen of erlotinib and rapamycin for a pediatric anaplastic oligodendroglioma refractory to standard treatment, achieving a 33-month sustained response. Immunohistochemical analysis of total and phosphorylated protein isoforms showed abnormal signaling consistent with detected mutations, while revealing heterogeneity in per-cell activation of signaling pathways in multiple subpopulations of tumor cells throughout the course of disease. This case highlights molecular features that may be relevant to designing future targeted treatments.
DOI: 10.1002/pbc.28750
PubMed: 33001573
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sustained response to erlotinib and rapamycin in a patient with pediatric anaplastic oligodendroglioma.</title><author><name sortKey="Geben, Laura C" sort="Geben, Laura C" uniqKey="Geben L" first="Laura C" last="Geben">Laura C. Geben</name><affiliation wicri:level="2"><nlm:affiliation>Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Program in Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Program in Pharmacology, Vanderbilt University School of Medicine, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Mobley, Bret C" sort="Mobley, Bret C" uniqKey="Mobley B" first="Bret C" last="Mobley">Bret C. Mobley</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Pathology, Microbiology, & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Departments of Pathology, Microbiology, & Immunology, Vanderbilt University Medical Center, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Vanderbilt Ingram Cancer Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Vanderbilt Ingram Cancer Center, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Brockman, Asa A" sort="Brockman, Asa A" uniqKey="Brockman A" first="Asa A" last="Brockman">Asa A. Brockman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Pastakia, Devang" sort="Pastakia, Devang" uniqKey="Pastakia D" first="Devang" last="Pastakia">Devang Pastakia</name><affiliation wicri:level="2"><nlm:affiliation>Monroe Carell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Hematology-Oncology, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Monroe Carell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Hematology-Oncology, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Departments of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Departments of Pediatrics, Vanderbilt University Medical Center, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Vanderbilt Ingram Cancer Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Vanderbilt Ingram Cancer Center, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Naftel, Rob" sort="Naftel, Rob" uniqKey="Naftel R" first="Rob" last="Naftel">Rob Naftel</name><affiliation wicri:level="2"><nlm:affiliation>Monroe Carell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Hematology-Oncology, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Monroe Carell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Hematology-Oncology, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Departments of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Departments of Neurological Surgery, Vanderbilt University Medical Center, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Vanderbilt Ingram Cancer Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Vanderbilt Ingram Cancer Center, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Ihrie, Rebecca A" sort="Ihrie, Rebecca A" uniqKey="Ihrie R" first="Rebecca A" last="Ihrie">Rebecca A. Ihrie</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Departments of Neurological Surgery, Vanderbilt University Medical Center, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Vanderbilt Ingram Cancer Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Vanderbilt Ingram Cancer Center, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Esbenshade, Adam J" sort="Esbenshade, Adam J" uniqKey="Esbenshade A" first="Adam J" last="Esbenshade">Adam J. Esbenshade</name><affiliation wicri:level="2"><nlm:affiliation>Monroe Carell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Hematology-Oncology, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Monroe Carell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Hematology-Oncology, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Departments of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Departments of Pediatrics, Vanderbilt University Medical Center, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Vanderbilt Ingram Cancer Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Vanderbilt Ingram Cancer Center, Nashville</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33001573</idno><idno type="pmid">33001573</idno><idno type="doi">10.1002/pbc.28750</idno><idno type="wicri:Area/Main/Corpus">000019</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000019</idno><idno type="wicri:Area/Main/Curation">000019</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000019</idno><idno type="wicri:Area/Main/Exploration">000019</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Sustained response to erlotinib and rapamycin in a patient with pediatric anaplastic oligodendroglioma.</title><author><name sortKey="Geben, Laura C" sort="Geben, Laura C" uniqKey="Geben L" first="Laura C" last="Geben">Laura C. Geben</name><affiliation wicri:level="2"><nlm:affiliation>Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Program in Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Program in Pharmacology, Vanderbilt University School of Medicine, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Mobley, Bret C" sort="Mobley, Bret C" uniqKey="Mobley B" first="Bret C" last="Mobley">Bret C. Mobley</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Pathology, Microbiology, & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Departments of Pathology, Microbiology, & Immunology, Vanderbilt University Medical Center, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Vanderbilt Ingram Cancer Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Vanderbilt Ingram Cancer Center, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Brockman, Asa A" sort="Brockman, Asa A" uniqKey="Brockman A" first="Asa A" last="Brockman">Asa A. Brockman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Pastakia, Devang" sort="Pastakia, Devang" uniqKey="Pastakia D" first="Devang" last="Pastakia">Devang Pastakia</name><affiliation wicri:level="2"><nlm:affiliation>Monroe Carell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Hematology-Oncology, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Monroe Carell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Hematology-Oncology, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Departments of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Departments of Pediatrics, Vanderbilt University Medical Center, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Vanderbilt Ingram Cancer Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Vanderbilt Ingram Cancer Center, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Naftel, Rob" sort="Naftel, Rob" uniqKey="Naftel R" first="Rob" last="Naftel">Rob Naftel</name><affiliation wicri:level="2"><nlm:affiliation>Monroe Carell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Hematology-Oncology, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Monroe Carell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Hematology-Oncology, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Departments of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Departments of Neurological Surgery, Vanderbilt University Medical Center, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Vanderbilt Ingram Cancer Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Vanderbilt Ingram Cancer Center, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Ihrie, Rebecca A" sort="Ihrie, Rebecca A" uniqKey="Ihrie R" first="Rebecca A" last="Ihrie">Rebecca A. Ihrie</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Departments of Neurological Surgery, Vanderbilt University Medical Center, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Vanderbilt Ingram Cancer Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Vanderbilt Ingram Cancer Center, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Esbenshade, Adam J" sort="Esbenshade, Adam J" uniqKey="Esbenshade A" first="Adam J" last="Esbenshade">Adam J. Esbenshade</name><affiliation wicri:level="2"><nlm:affiliation>Monroe Carell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Hematology-Oncology, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Monroe Carell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Hematology-Oncology, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Departments of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Departments of Pediatrics, Vanderbilt University Medical Center, Nashville</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:affiliation>Vanderbilt Ingram Cancer Center, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Vanderbilt Ingram Cancer Center, Nashville</wicri:cityArea></affiliation></author></analytic><series><title level="j">Pediatric blood & cancer</title><idno type="eISSN">1545-5017</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">One goal of precision medicine is to identify mutations within individual tumors to design targeted treatment approaches. This report details the use of genomic testing to select a targeted therapy regimen of erlotinib and rapamycin for a pediatric anaplastic oligodendroglioma refractory to standard treatment, achieving a 33-month sustained response. Immunohistochemical analysis of total and phosphorylated protein isoforms showed abnormal signaling consistent with detected mutations, while revealing heterogeneity in per-cell activation of signaling pathways in multiple subpopulations of tumor cells throughout the course of disease. This case highlights molecular features that may be relevant to designing future targeted treatments.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">33001573</PMID><DateRevised><Year>2020</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-5017</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Pediatric blood & cancer</Title><ISOAbbreviation>Pediatr Blood Cancer</ISOAbbreviation></Journal><ArticleTitle>Sustained response to erlotinib and rapamycin in a patient with pediatric anaplastic oligodendroglioma.</ArticleTitle><Pagination><MedlinePgn>e28750</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pbc.28750</ELocationID><Abstract><AbstractText>One goal of precision medicine is to identify mutations within individual tumors to design targeted treatment approaches. This report details the use of genomic testing to select a targeted therapy regimen of erlotinib and rapamycin for a pediatric anaplastic oligodendroglioma refractory to standard treatment, achieving a 33-month sustained response. Immunohistochemical analysis of total and phosphorylated protein isoforms showed abnormal signaling consistent with detected mutations, while revealing heterogeneity in per-cell activation of signaling pathways in multiple subpopulations of tumor cells throughout the course of disease. This case highlights molecular features that may be relevant to designing future targeted treatments.</AbstractText><CopyrightInformation>© 2020 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Geben</LastName><ForeName>Laura C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mobley</LastName><ForeName>Bret C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Departments of Pathology, Microbiology, & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Ingram Cancer Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brockman</LastName><ForeName>Asa A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastakia</LastName><ForeName>Devang</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Monroe Carell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Hematology-Oncology, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Ingram Cancer Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naftel</LastName><ForeName>Rob</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Monroe Carell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Hematology-Oncology, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Ingram Cancer Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ihrie</LastName><ForeName>Rebecca A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Departments of Neurological Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Ingram Cancer Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell & Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esbenshade</LastName><ForeName>Adam J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-0154-4996</Identifier><AffiliationInfo><Affiliation>Monroe Carell Jr. Children's Hospital at Vanderbilt, Division of Pediatric Hematology-Oncology, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Ingram Cancer Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>W81XWH-16-1-0171</GrantID><Agency>U.S. Department of Defense</Agency><Country></Country></Grant><Grant><GrantID>R01 NS096238</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007628</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Eric T. Klindt Fund for Brain Cancer Research</Agency><Country></Country></Grant><Grant><GrantID>TS150037</GrantID><Agency>U.S. Department of Defense</Agency><Country></Country></Grant><Grant><Agency>Michael David Greene Brain Cancer Fund</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Blood Cancer</MedlineTA><NlmUniqueID>101186624</NlmUniqueID><ISSNLinking>1545-5009</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EGFR</Keyword><Keyword MajorTopicYN="N">brain tumor</Keyword><Keyword MajorTopicYN="N">mTOR</Keyword><Keyword MajorTopicYN="N">neuro-oncology</Keyword><Keyword MajorTopicYN="N">pediatric oncology</Keyword><Keyword MajorTopicYN="N">targeted therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>09</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>09</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33001573</ArticleId><ArticleId IdType="doi">10.1002/pbc.28750</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the Rosetta Stone of therapy resistance. Cancer Cell. 2020;37(4):471-484.</Citation></Reference><Reference><Citation>Johnson A, Severson E, Gay L, et al. Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist. 2017;22(12):1478-1490.</Citation></Reference><Reference><Citation>Salloum R, McConechy MK, Mikael LG, et al. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. Acta Neuropathol Commun. 2017;5(1):78.</Citation></Reference><Reference><Citation>Aihara K, Mukasa A, Nagae G, et al. Genetic and epigenetic stability of oligodendrogliomas at recurrence. Acta Neuropathol Commun. 2017;5(1):18.</Citation></Reference><Reference><Citation>Mackay A, Burford A, Carvalho D, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell. 2017;32(4):520-537.e5.</Citation></Reference><Reference><Citation>Yalon M, Rood B, MacDonald TJ, et al. A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Pediatr Blood Cancer. 2013;60(1):71-76.</Citation></Reference><Reference><Citation>Gerdes MJ, Sevinsky CJ, Sood A, et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A. 2013;110(29):11982-11987.</Citation></Reference><Reference><Citation>Lin JR, Izar B, Wang S, et al. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. Elife. 2018;7:e31657.</Citation></Reference><Reference><Citation>Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 2020;37(4):543-550.</Citation></Reference><Reference><Citation>Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;169(2):361-371.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Tennessee</li></region></list><tree><country name="États-Unis"><region name="Tennessee"><name sortKey="Geben, Laura C" sort="Geben, Laura C" uniqKey="Geben L" first="Laura C" last="Geben">Laura C. Geben</name></region><name sortKey="Brockman, Asa A" sort="Brockman, Asa A" uniqKey="Brockman A" first="Asa A" last="Brockman">Asa A. Brockman</name><name sortKey="Esbenshade, Adam J" sort="Esbenshade, Adam J" uniqKey="Esbenshade A" first="Adam J" last="Esbenshade">Adam J. Esbenshade</name><name sortKey="Esbenshade, Adam J" sort="Esbenshade, Adam J" uniqKey="Esbenshade A" first="Adam J" last="Esbenshade">Adam J. Esbenshade</name><name sortKey="Esbenshade, Adam J" sort="Esbenshade, Adam J" uniqKey="Esbenshade A" first="Adam J" last="Esbenshade">Adam J. Esbenshade</name><name sortKey="Geben, Laura C" sort="Geben, Laura C" uniqKey="Geben L" first="Laura C" last="Geben">Laura C. Geben</name><name sortKey="Ihrie, Rebecca A" sort="Ihrie, Rebecca A" uniqKey="Ihrie R" first="Rebecca A" last="Ihrie">Rebecca A. Ihrie</name><name sortKey="Ihrie, Rebecca A" sort="Ihrie, Rebecca A" uniqKey="Ihrie R" first="Rebecca A" last="Ihrie">Rebecca A. Ihrie</name><name sortKey="Ihrie, Rebecca A" sort="Ihrie, Rebecca A" uniqKey="Ihrie R" first="Rebecca A" last="Ihrie">Rebecca A. Ihrie</name><name sortKey="Mobley, Bret C" sort="Mobley, Bret C" uniqKey="Mobley B" first="Bret C" last="Mobley">Bret C. Mobley</name><name sortKey="Mobley, Bret C" sort="Mobley, Bret C" uniqKey="Mobley B" first="Bret C" last="Mobley">Bret C. Mobley</name><name sortKey="Naftel, Rob" sort="Naftel, Rob" uniqKey="Naftel R" first="Rob" last="Naftel">Rob Naftel</name><name sortKey="Naftel, Rob" sort="Naftel, Rob" uniqKey="Naftel R" first="Rob" last="Naftel">Rob Naftel</name><name sortKey="Naftel, Rob" sort="Naftel, Rob" uniqKey="Naftel R" first="Rob" last="Naftel">Rob Naftel</name><name sortKey="Pastakia, Devang" sort="Pastakia, Devang" uniqKey="Pastakia D" first="Devang" last="Pastakia">Devang Pastakia</name><name sortKey="Pastakia, Devang" sort="Pastakia, Devang" uniqKey="Pastakia D" first="Devang" last="Pastakia">Devang Pastakia</name><name sortKey="Pastakia, Devang" sort="Pastakia, Devang" uniqKey="Pastakia D" first="Devang" last="Pastakia">Devang Pastakia</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000041 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000041 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33001573
|texte= Sustained response to erlotinib and rapamycin in a patient with pediatric anaplastic oligodendroglioma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33001573" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |